Skip to main content
Article

Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions

Moein ShirzadPharmaceutical Technology Institute, Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, IranMina ShabanPharmaceutical Technology Institute, Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, IranVahideh MohammadzadehPharmaceutical Technology Institute, Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, IranAbbas RahdarDepartment of Physics, University of Zabol, Zabol, IranSonia Fathi‐karkanDepartment of Medical Nanotechnology, School of Medicine, North Khorasan University of Medical Science, Bojnurd, IranZakieh Sadat HoseiniDepartment of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranMehrdad NajafiDepartment of Chemical Engineering, Sharif University of Technology, Tehran, IranZelal KharabaDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesM. Ali AboudzadehPOLYMAT and Department of Applied Chemistry, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel de Lardizabal 3, 20018, Donostia-San Sebastián, Spain
2025en
ABI

Abstract

Abstract This paper explores the revolutionary collaboration between artificial intelligence (AI) and nanotechnology in detecting and treating breast cancer. It highlights the synergistic potential of both fields to overcome significant limitations of modern approaches. Clinical applications and research demonstrate the diversity and depth of AI-based deep learning models in diagnostics, improving diagnostic accuracy and enabling precise, individualized therapy through advanced imaging and biomarker discovery. Through intelligent nanocarriers, nanotechnology contributes to these advancements by enabling targeted drug delivery, minimizing systemic toxicity, and providing theranostic capabilities for real-time monitoring. However, challenges remain, including data accessibility, model interpretability, scalability in nanocarrier manufacturing, and tumor diversity. Future improvements should focus on developing multifunctional nanoparticles, flexible AI algorithms, and scalable, cost-effective solutions to enhance accessibility and clinical integration. Hence, the study emphasizes the need for multidisciplinary collaboration to eliminate existing barriers and generate advancements to transform breast cancer therapies into more effective, safer, and individualized methods. Graphical Abstract

Identifiers

Citations and references

Cited by 20 references